Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

SOHO 2020

Myelodysplastic Syndromes

View all
3:00
APR-246 in TP53 mutated MDS and AML
David Sallman • 3 Sep 2020
1:36
LB-100 in low and intermediate risk MDS
Rami Komrokji • 23 Aug 2020

Myeloproliferative Neoplasms

View all
3:51
New therapies for myelofibrosis
Srdan Verstovsek • 30 Aug 2020
2:12
Genomics in myelofibrosis: practical guidelines for its use in clinical practice
Raajit Rampal • 25 Aug 2020

Chronic Lymphocytic Leukemia

View all
2:32
Value of MRD measurement in CLL
Michael Hallek • 27 Aug 2020
5:22
Long-term outcomes of anti-CD19 CAR-T in R/R CLL
David Porter • 1 Sep 2020
2:24
BCL-2 frontline therapy in CLL
Michael Hallek • 25 Aug 2020
2:32
Discussing MRD testing with patients
William Wierda • 10 Sep 2020

Acute Myeloid Leukemia

View all
4:16
Updates from AMG 330 in AML
Marion Subklewe • 1 Sep 2020
2:14
COVID-19 impact on AML: German perspective
Marion Subklewe • 31 Aug 2020
1:57
Glasdegib as maintenance therapy in AML and MDS
Daniel Pollyea • 3 Sep 2020
3:00
APR-246 in TP53 mutated MDS and AML
David Sallman • 3 Sep 2020

Amyloidoisis

View all
2:50
Unmet needs in amyloidosis
Suzanne Lentzsch • 1 Sep 2020
2:55
Chemotherapy-free approaches to AL amyloidosis
Suzanne Lentzsch • 27 Aug 2020

Multiple Myeloma

View all
2:10
Why should smoldering myeloma be treated early?
Maria Victoria-Mateos • 26 Aug 2020
5:52
BCMA targeting agents in myeloma
Nikhil Munshi • 9 Sep 2020
The content of VJHemOnc is intended for healthcare professionals